What is INQOVI?

Learn more about INQOVI from this panel discussion

View a panel discussion between a well-respected hematologist-oncologist, nurse practitioner, and patient caregiver advocate on the topic of myelodysplastic syndromes (MDS) treatment at home—including the advantages and disadvantages of current treatment options, patient care, and INQOVI.

Receiving treatment for MDS, including CMML, can be challenging1,3*

For some patients and caregivers, this requires:

Additional travel to and from chemotherapy infusion centers or hospitals for IV infusions or subcutaneous injections

  • Visits may be long and frequent, for multiple cycles (5–7 days/cycle)3,4
Icon of a hospital representing chemotherapy infusion centers

Venous access and parenteral administration1,5

Icon of a syringe representing venous access and parenteral administration

Premature treatment discontinuation may be a concern for MDS patients

Of 664 higher-risk patients, 295 (44.4%) were nonpersistent with HMA treatment (nonpersistence is defined by the investigators as <4 cycles or a gap of ≥90 days between cycles)6

  • This finding is based on a retrospective analysis of the SEER database and did not measure treatment outcomes. Therefore, these data should be interpreted with caution
  • Additional steps (such as closer care management and follow up) may be needed to help improve patient continuation on HMA treatment in the higher-risk patient population6,7
[<4 icon/graphic - see screenshot attached](comment 101)

*Especially in the case of transplant-ineligible patients.

Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database between 2010 and 2016.


Cedazuridine enables oral delivery of decitabine9

INQOVI® tablets are 1 pill, taken once daily for 5 days out of a 28-day cycle. See full dosing information here. INQOVI is a fixed-dose combination of decitabine (35 mg) and cedazuridine (100 mg), a cytidine deaminase inhibitor that enhances oral bioavailability of decitabine and also increases its systemic exposure.

A chart depicting the mechanism of action for INQOVI A chart depicting the mechanism of action for INQOVI
  • Decitabine is a nucleoside metabolic inhibitor believed to exert its effects through DNA hypomethylation. This may restore normal function to genes critical for the control of cellular differentiation and proliferation
    • Nonproliferating cells are relatively insensitive to decitabine
  • Cytidine deaminase (CDA) is an enzyme responsible for degradation of nucleosides such as decitabine into inactive metabolites, limiting their oral bioavailability
  • Administration of cedazuridine with decitabine increases systemic exposure of decitabine

DNMT=DNA methyltransferase.

References: 1. Steensma DP, Komrokji RS, Stone RM, et al. Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer. 2014;120(11):1670‑1676. 2. Bell JA, Galaznik A, Blazer M, et al. Economic burden of patients treated for higher‑risk myelodysplastic syndromes (HR‑MDS) in routine clinical care in the United States. PharmacoEconomics Open. 2019;3(2): 237‑245. 3. Savona MR, Odenike O, Amrein PC, et al. An oral fixed‑dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open‑label, dose‑escalation, phase 1 study. Lancet Haematol. 2019;6(4): e194‑e203. doi:10.1016/S2352‑3026(19)30030‑4 4. Vidaza [package insert]. Summit, NJ: Celgene Corporation; 2020. 5. Leveque D. Subcutaneous administration of anticancer agents. Anticancer Research. 2014;34(4):1579‑1586. 6. Joshi N, Kale H, Corman S, et al. Direct medical costs associated with treatment nonpersistence in patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents: A large retrospective cohort analysis. Clin Lymphoma Myeloma Leuk. 2021;21(3):e248-e254. 7. Kini V, Ho PM. Interventions to improve medication adherence: A review. JAMA. 2018 Dec 18;320(23):2461-2473. 8. Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096‑1107. 9. INQOVI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2022

Previous Page 


Next Page 

Appropriate Patients